Tirzepatide is a dual GIP/GLP-1 receptor agonist representing the next generation of weight loss peptides.

How Tirzepatide Works

Unlike semaglutide (GLP-1 only), tirzepatide activates both GIP and GLP-1 receptors for enhanced effects.

Research Results

• 15-20%+ body weight reduction
• Superior to semaglutide in studies
• Improved glycemic control

Dosing Protocol

Research starts at 2.5mg weekly, titrating up to 15mg over months.

Research peptides are NOT equivalent to FDA-approved Mounjaro.